| http://dbpedia.org/ontology/abstract
|
بريفاراسيتام (بالإنجليزية: Brivaracetam) هو دواء يُستعمل في علاج:
* صرع (منذ 12 مايو 2016)
, Il brivaracetam è un farmaco appartenente … Il brivaracetam è un farmaco appartenente alla famiglia dei racetam, il cui precursore è il piracetam. A differenza di altri suoi congeneri strutturali, però, non possiede proprietà nootropiche, bensì antiepilettiche. Tuttavia non è attivo in manifestazioni acute (da elettroshock o ) ma protegge dalle manifestazioni motorie secondarie. Chimicamente è il derivato n-propilico del levetiracetam ed è dotato di buone proprietà idrofobe, tali da consentirgli un rapido passaggio attraverso la barriera ematoencefalica. Il suo meccanismo d'azione sembra multiplo. Può bloccare infatti le correnti del sodio voltaggio-dipendenti, facilitare la correnti del potassio attraverso i canali KCNQ ed interagire con la proteina SV2 delle vescicole . Una volta somministrato, il farmaco è assorbito completamente entro 2 ore e soltanto un 20% di esso è trovato legato alle proteine plasmatiche. La sua emivita è di 7-8 ore, viene metabolizzato a livello epatico dal citocromo P450 2C8 e la sua clearance renale è bassa. Entro 72 ore dalla somministrazione, il 95% del farmaco si ritrova nelle urine. Uno studio controllato sull'efficacia del farmaco è stato pubblicato pochi mesi fa https://www.ncbi.nlm.nih.gov/pubmed/26920914tps://www.ncbi.nlm.nih.gov/pubmed/26920914
, Brivaracetam, sold under the brand names B … Brivaracetam, sold under the brand names Briviact and Brivajoy among others, a chemical analog of levetiracetam, is a racetam derivative with anticonvulsant (antiepileptic) properties. It is marketed by the pharmaceutical company UCB. It is available as a generic medication.. It is available as a generic medication.
, Briwaracetam – organiczny związek chemiczn … Briwaracetam – organiczny związek chemiczny, lek przeciwpadaczkowy zbliżony pod względem struktury i mechanizmu działania do lewetyracetamu, w porównaniu do którego osiąga skuteczność kliniczną przy niższych dawkach. W 2016 został zaakceptowany przez Europejską Agencje Leków ze wskazaniem w terapii wspomagającej w leczeniu padaczki u pacjentów powyżej 16. roku życia. Dostępny pod nazwą handlową Briviact.cia. Dostępny pod nazwą handlową Briviact.
, Brivaracetam ist ein antiepileptisch wirks … Brivaracetam ist ein antiepileptisch wirksamer Arzneistoff. Er wurde von der belgischen Firma UCB entwickelt und im Januar 2016 in der EU und im Februar 2016 in den USA unter dem Namen Briviact zur Zusatzbehandlung fokaler Epilepsieanfälle zugelassen bei Erwachsenen und Jugendlichen ab 16 Jahren. Fokale Anfälle sind Anfälle, die auf einer Seite des Gehirns beginnen. Bei Ausbreitung können sie größere Bereiche auf beiden Seiten des Gehirns beeinträchtigen („sekundäre Generalisierung“).nträchtigen („sekundäre Generalisierung“).
|
| http://dbpedia.org/ontology/alternativeName
|
Briviact, Nubriveo, Brivajoy
|
| http://dbpedia.org/ontology/casNumber
|
357336-20-0
|
| http://dbpedia.org/ontology/chEBI
|
133013
|
| http://dbpedia.org/ontology/chEMBL
|
607400
|
| http://dbpedia.org/ontology/drugbank
|
DB05541
|
| http://dbpedia.org/ontology/fdaUniiCode
|
U863JGG2IA
|
| http://dbpedia.org/ontology/kegg
|
D08879
|
| http://dbpedia.org/ontology/medlinePlus
|
a616027
|
| http://dbpedia.org/ontology/pubchem
|
9837243
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Brivaracetam.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://www.ncbi.nlm.nih.gov/books/NBK61999/ +
, https://www.ncbi.nlm.nih.gov/books/NBK500036/ +
, https://druginfo.nlm.nih.gov/drugportal/name/brivaracetam +
|
| http://dbpedia.org/ontology/wikiPageID
|
12434982
|
| http://dbpedia.org/ontology/wikiPageLength
|
17999
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1124286445
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Metabolize +
, http://dbpedia.org/resource/UCB_%28company%29 +
, http://dbpedia.org/resource/File:Levetiracetam.svg +
, http://dbpedia.org/resource/Levetiracetam +
, http://dbpedia.org/resource/Category:Anticonvulsants +
, http://dbpedia.org/resource/Category:Racetams +
, http://dbpedia.org/resource/Chemical_analogue +
, http://dbpedia.org/resource/Nausea +
, http://dbpedia.org/resource/Dizziness +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Hydroxylation +
, http://dbpedia.org/resource/CYP2C19 +
, http://dbpedia.org/resource/Phenytoin +
, http://dbpedia.org/resource/Intravenous_therapy +
, http://dbpedia.org/resource/Urine +
, http://dbpedia.org/resource/Active_metabolite +
, http://dbpedia.org/resource/Synaptic_vesicle_glycoprotein_2A +
, http://dbpedia.org/resource/Hydrolysis +
, http://dbpedia.org/resource/Category:Carboxamides +
, http://dbpedia.org/resource/Carbamazepine +
, http://dbpedia.org/resource/Plasma_protein_binding +
, http://dbpedia.org/resource/Racetam +
, http://dbpedia.org/resource/Controlled_Substances_Act +
, http://dbpedia.org/resource/Anticonvulsant +
, http://dbpedia.org/resource/National_Center_for_Biotechnology_Information +
, http://dbpedia.org/resource/Generic_medication +
, http://dbpedia.org/resource/Acetamide +
, http://dbpedia.org/resource/Amidase +
, http://dbpedia.org/resource/Standard_for_the_Uniform_Scheduling_of_Medicines_and_Poisons +
, http://dbpedia.org/resource/Kidney +
, http://dbpedia.org/resource/Drug_Enforcement_Administration +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/European_Commission +
|
| http://dbpedia.org/property/atcPrefix
|
N03
|
| http://dbpedia.org/property/atcSuffix
|
AX23
|
| http://dbpedia.org/property/bioavailability
|
Nearly 100%
|
| http://dbpedia.org/property/c
|
11
|
| http://dbpedia.org/property/casNumber
|
357336
|
| http://dbpedia.org/property/chebi
|
133013
|
| http://dbpedia.org/property/chembl
|
607400
|
| http://dbpedia.org/property/chemspiderid
|
8012964
|
| http://dbpedia.org/property/dailymedid
|
Brivaracetam
|
| http://dbpedia.org/property/date
|
May 2016
|
| http://dbpedia.org/property/drugbank
|
DB05541
|
| http://dbpedia.org/property/eliminationHalfLife
|
32400.0
|
| http://dbpedia.org/property/excretion
|
Kidneys
|
| http://dbpedia.org/property/h
|
20
|
| http://dbpedia.org/property/iupacName
|
-2
|
| http://dbpedia.org/property/kegg
|
D08879
|
| http://dbpedia.org/property/legalAu
|
S4
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalStatus
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Schedule V
|
| http://dbpedia.org/property/licenceEu
|
yes
|
| http://dbpedia.org/property/medlineplus
|
a616027
|
| http://dbpedia.org/property/meltingHigh
|
77
|
| http://dbpedia.org/property/meltingPoint
|
72
|
| http://dbpedia.org/property/metabolism
|
Hydrolysis by amidase, CYP2C19-mediated hydroxylation
|
| http://dbpedia.org/property/metabolites
|
3
|
| http://dbpedia.org/property/n
|
2
|
| http://dbpedia.org/property/o
|
2
|
| http://dbpedia.org/property/pregnancyAu
|
B3
|
| http://dbpedia.org/property/proteinBound
|
≤20%
|
| http://dbpedia.org/property/pubchem
|
9837243
|
| http://dbpedia.org/property/reason
|
What is "interim final"? Seems contradictory.
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Intravenous_therapy +
, http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/smiles
|
O=C[C@@H]CC
|
| http://dbpedia.org/property/specificRotation
|
[α]D −60°
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
MSYKRHVOOPPJKU-BDAKNGLRSA-N
|
| http://dbpedia.org/property/tradename
|
Briviact, Nubriveo, Brivajoy
|
| http://dbpedia.org/property/unii
|
U863JGG2IA
|
| http://dbpedia.org/property/width
|
130
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Anticonvulsants +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Clarify +
, http://dbpedia.org/resource/Template:Cite_book +
, http://dbpedia.org/resource/Template:Clear_left +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Respell +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:As_of +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Racetams +
, http://dbpedia.org/resource/Template:IPAc-en +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Ebicite +
, http://dbpedia.org/resource/Template:Stdinchicite +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Anticonvulsants +
, http://dbpedia.org/resource/Category:Carboxamides +
, http://dbpedia.org/resource/Category:Racetams +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Racetam +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Brivaracetam?oldid=1124286445&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Levetiracetam.svg +
, http://commons.wikimedia.org/wiki/Special:FilePath/Brivaracetam.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Brivaracetam +
|
| owl:sameAs |
http://ro.dbpedia.org/resource/Brivaracetam +
, http://yago-knowledge.org/resource/Brivaracetam +
, http://it.dbpedia.org/resource/Brivaracetam +
, http://sr.dbpedia.org/resource/Brivaracetam +
, http://sh.dbpedia.org/resource/Brivaracetam +
, http://www.wikidata.org/entity/Q408099 +
, http://pl.dbpedia.org/resource/Briwaracetam +
, http://de.dbpedia.org/resource/Brivaracetam +
, http://ar.dbpedia.org/resource/%D8%A8%D8%B1%D9%8A%D9%81%D8%A7%D8%B1%D8%A7%D8%B3%D9%8A%D8%AA%D8%A7%D9%85 +
, http://tr.dbpedia.org/resource/Brivarasetam +
, http://vi.dbpedia.org/resource/Brivaracetam +
, http://fa.dbpedia.org/resource/%D8%A8%D8%B1%DB%8C%D9%88%D8%A7%D8%B1%D8%A7%D8%B3%D8%AA%D8%A7%D9%85 +
, http://or.dbpedia.org/resource/%E0%AC%AC%E0%AD%8D%E0%AC%B0%E0%AC%BF%E0%AC%AD%E0%AC%BE%E0%AC%B0%E0%AC%BE%E0%AC%B8%E0%AD%87%E0%AC%9F%E0%AC%AE +
, http://rdf.freebase.com/ns/m.02w5n5f +
, http://dbpedia.org/resource/Brivaracetam +
, https://global.dbpedia.org/id/3mh9h +
|
| rdf:type |
http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/HeterocyclicCompound115025397 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/ontology/ChemicalCompound +
, http://dbpedia.org/class/yago/Amide114724264 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/WikicatAmides +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/WikicatNitrogenHeterocycles +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://umbel.org/umbel/rc/ChemicalSubstanceType +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
|
| rdfs:comment |
بريفاراسيتام (بالإنجليزية: Brivaracetam) هو دواء يُستعمل في علاج:
* صرع (منذ 12 مايو 2016)
, Brivaracetam ist ein antiepileptisch wirks … Brivaracetam ist ein antiepileptisch wirksamer Arzneistoff. Er wurde von der belgischen Firma UCB entwickelt und im Januar 2016 in der EU und im Februar 2016 in den USA unter dem Namen Briviact zur Zusatzbehandlung fokaler Epilepsieanfälle zugelassen bei Erwachsenen und Jugendlichen ab 16 Jahren. Fokale Anfälle sind Anfälle, die auf einer Seite des Gehirns beginnen. Bei Ausbreitung können sie größere Bereiche auf beiden Seiten des Gehirns beeinträchtigen („sekundäre Generalisierung“).nträchtigen („sekundäre Generalisierung“).
, Brivaracetam, sold under the brand names B … Brivaracetam, sold under the brand names Briviact and Brivajoy among others, a chemical analog of levetiracetam, is a racetam derivative with anticonvulsant (antiepileptic) properties. It is marketed by the pharmaceutical company UCB. It is available as a generic medication.. It is available as a generic medication.
, Briwaracetam – organiczny związek chemiczn … Briwaracetam – organiczny związek chemiczny, lek przeciwpadaczkowy zbliżony pod względem struktury i mechanizmu działania do lewetyracetamu, w porównaniu do którego osiąga skuteczność kliniczną przy niższych dawkach. W 2016 został zaakceptowany przez Europejską Agencje Leków ze wskazaniem w terapii wspomagającej w leczeniu padaczki u pacjentów powyżej 16. roku życia. Dostępny pod nazwą handlową Briviact.cia. Dostępny pod nazwą handlową Briviact.
, Il brivaracetam è un farmaco appartenente … Il brivaracetam è un farmaco appartenente alla famiglia dei racetam, il cui precursore è il piracetam. A differenza di altri suoi congeneri strutturali, però, non possiede proprietà nootropiche, bensì antiepilettiche. Tuttavia non è attivo in manifestazioni acute (da elettroshock o ) ma protegge dalle manifestazioni motorie secondarie. Chimicamente è il derivato n-propilico del levetiracetam ed è dotato di buone proprietà idrofobe, tali da consentirgli un rapido passaggio attraverso la barriera ematoencefalica.io attraverso la barriera ematoencefalica.
|
| rdfs:label |
Brivaracetam
, Briwaracetam
, بريفاراسيتام
|
